Zachary Oman, DO
Interventional Cardiology · Grand Island, NENPI 1326492802
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 35.0% of the total. Reporting peaked in 2023 at $6,611 and has fallen 67.9% since, to $2,125 in 2025.
Across 301 payments — averaging $55.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$2K
- Abiomed$2K
- Edwards Lifesciences$1K
- Philips North America LLC$1K
- Inari Medical, Inc.$744
- plus $2K from 28 others
What the payments were for
- Travel & lodging$7,53345%
- Food & beverage$8,75652%
- Education$4933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 104 | $5,878 |
| Abbott | 24 | $2,460 |
| Abiomed | 12 | $2,429 |
| Edwards Lifesciences | 10 | $1,494 |
| Philips North America LLC | 8 | $1,319 |
| Inari Medical, Inc. | 44 | $744 |
| Stryker | 37 | $529 |
| Asahi Intecc USA, Inc. | 4 | $278 |
| Cardiovascular Systems Inc. | 4 | $187 |
| Boston Scientific | 2 | $167 |
| AstraZeneca | 7 | $147 |
| Terumo Medical Corporation | 5 | $139 |
| Cardiva Medical, Inc. | 1 | $122 |
| United Therapeutics Corporation | 3 | $120 |
| Lexicon Pharmaceuticals, Inc. | 4 | $106 |
| Chiesi USA, Inc. | 3 | $88 |
| E.r. Squibb & Sons, L.L.C. | 3 | $77 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $64 |
| Pfizer | 3 | $53 |
| Shockwave Medical, Inc | 2 | $36 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Novartis | 2 | $35 |
| W. L. Gore & Associates, Inc. | 1 | $33 |
| Bard Peripheral Vascular, Inc. | 2 | $32 |
| Penumbra, Inc. | 1 | $29 |
| Bayer | 2 | $28 |
| Merck | 2 | $27 |
| Cordis US CORP. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Angiodynamics, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| GSK | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$2,182
- TurboHawk$1,454
- Perclose ProStyle$1,135
- US Und$1,052
- IN.PACT Admiral$761
- Abre$539
- Edwards SAPIEN 3 Transcatheter Heart Valve$426
- HawkOne$295
- Resolute$268
- ENSITE$199
- GENERAL VASCULAR ACCESS$162
- RESOLUTE ONYX$149
- Diamondback Coronary$148
- ENSITE PRECISION$137
- Cardiva VASCADE 6/7F VCS$122
- Perclose ProGlide suture mediated closure system$119
- Ensite Cardiac Mapping System$117
- ONYX FRONTIER$112
- Assurity Pacemaker$110
- Fortify Assura, Ellipse ICD$100
How this compares
$16,782 in reported general payments places this provider in the 75th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 113 | $84,106 |
| EntrestoSacubitril/Valsartan | 82 | $73,579 |
| EliquisApixaban | 71 | $66,652 |
| JardianceEmpagliflozin | 28 | $28,405 |
| Repatha SureclickEvolocumab | 25 | $20,891 |
| FarxigaDapagliflozin Propanediol | 28 | $18,299 |
| BrilintaTicagrelor | 25 | $14,986 |
| Praluent PenAlirocumab | 15 | $8,269 |
| Rosuvastatin Calcium | 210 | $2,507 |
| Metoprolol Succinate | 157 | $2,350 |
| FenofibrateFenofibrate Nanocrystallized | 37 | $1,909 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 64 | $1,607 |
| Torsemide | 57 | $1,312 |
| Atorvastatin Calcium | 143 | $1,289 |
| Losartan Potassium | 109 | $1,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $35 | $73,57982 claims |
| PfizerEliquis | $53 | $66,65271 claims |
| AstraZenecaFarxiga, Brilinta | $147 | $33,28553 claims |
| Boehringer IngelheimJardiance | $16 | $28,40528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in Grand Island
- Erich FruehlingGrand Island$3K
- Douglas KosmickiGrand Island$3K
- Brock CookmanLincoln$782K
- Himanshu AgarwalOmaha$541K
- Matthew JohnsonLincoln$162K
- Poonam VelagapudiOmaha$142K
- Steven MartinLincoln$55K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- James HallKearney$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.